An 8-week, Open-label, Uncontrolled Study of Tamsulosin 0.4mg in Men With Bothersome Urinary Symptoms
Public ClinicalTrials.gov record NCT01726270. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A 8-week, Open-label, Uncontrolled, Exploratory Actual Use Study of Tamsulosin 0.4mg in Men With Prostate Urinary Symptoms in a Simulated Over-the-Counter Environment
Study identification
- NCT ID
- NCT01726270
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Enrollment
- 689 participants
Conditions and interventions
Conditions
Interventions
- tamsulosin Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 100 Years
- Sex
- Male
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 31, 2012
- Primary completion
- Feb 28, 2013
- Completion
- Feb 28, 2013
- Last update posted
- Mar 26, 2020
2012 – 2013
United States locations
- U.S. sites
- 18
- U.S. states
- 8
- U.S. cities
- 18
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Boehringer Ingelheim Investigational Site | Hoover | Alabama | — | — |
| Boehringer Ingelheim Investigational Site | Mesa | Arizona | — | — |
| Boehringer Ingelheim Investigational Site | Encino | California | — | — |
| Boehringer Ingelheim Investigational Site | Garden Grove | California | — | — |
| Boehringer Ingelheim Investigational Site | La Habra | California | — | — |
| Boehringer Ingelheim Investigational Site | Anoka | Minnesota | — | — |
| Boehringer Ingelheim Investigational Site | Elk River | Minnesota | — | — |
| Boehringer Ingelheim Investigational Site | Fridley | Minnesota | — | — |
| Boehringer Ingelheim Investigational Site | Roseville | Minnesota | — | — |
| Boehringer Ingelheim Investigational Site | Saint Francis | Minnesota | — | — |
| Boehringer Ingelheim Investigational Site | Albuquerque | New Mexico | — | — |
| Boehringer Ingelheim Investigational Site | Longview | Texas | — | — |
| Boehringer Ingelheim Investigational Site | Tyler | Texas | — | — |
| Boehringer Ingelheim Investigational Site | Bountiful | Utah | — | — |
| Boehringer Ingelheim Investigational Site | Layton | Utah | — | — |
| Boehringer Ingelheim Investigational Site | Salt Lake City | Utah | — | — |
| Boehringer Ingelheim Investigational Site | Syracuse | Utah | — | — |
| Boehringer Ingelheim Investigational Site | Richmond | Virginia | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01726270, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 26, 2020 · Synced Jul 23, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01726270 live on ClinicalTrials.gov.